No Clinically Significant Interaction Between Buspirone and L-Lysine
There are no documented pharmacokinetic or pharmacodynamic interactions between buspirone and L-lysine, and no dose adjustments are required when using these agents together.
Pharmacological Basis for Lack of Interaction
Buspirone Metabolism and Drug Interactions
Buspirone is extensively metabolized via CYP3A4 in the liver, with negligible renal excretion 1. The FDA drug label clearly identifies specific drug interactions that occur through:
- CYP3A4 inhibition (increasing buspirone levels): erythromycin, itraconazole, nefazodone, diltiazem, verapamil, ketoconazole, ritonavir 1
- CYP3A4 induction (decreasing buspirone levels): rifampin, carbamazepine, phenytoin, phenobarbital, dexamethasone 1
- P-glycoprotein effects: grapefruit juice significantly increases buspirone exposure 1
L-Lysine Pharmacology
L-lysine is an essential amino acid that does not undergo hepatic CYP450 metabolism. Systematic safety reviews of L-lysine supplementation (doses ranging from 16.8 mg to 17.5 g/day for periods up to 1095 days) identified only gastrointestinal symptoms as adverse events, with no drug-drug interactions reported 2, 3. The provisional no-observed-adverse-effect level was established at 6.0 g/day based on GI tolerability 2, 3.
Why No Interaction Exists
L-lysine does not:
- Inhibit or induce CYP3A4 enzymes
- Affect P-glycoprotein transport
- Interact with hepatic uptake transporters (OATP)
- Displace protein-bound drugs
- Share metabolic pathways with buspirone
The FDA label for buspirone specifically notes that therapeutic levels of various drugs had "only a limited effect on the extent of binding of buspirone to plasma proteins" 1. L-lysine, as an amino acid, would not be expected to alter buspirone protein binding.
Clinical Recommendation
Use buspirone and L-lysine together without dose modification. Standard buspirone dosing (typically 15-30 mg/day in divided doses) can be maintained when patients are taking L-lysine supplements 1.
Important Caveats
While no interaction exists between these two agents specifically, clinicians should remain vigilant for:
- Buspirone's documented interactions with CYP3A4 inhibitors/inducers that may be present in the patient's medication regimen 1
- Gastrointestinal symptoms from L-lysine at doses >6 g/day, which could be mistakenly attributed to buspirone 2, 3
- MAO inhibitor contraindication with buspirone (14-day washout required) 1
The absence of this drug pair in comprehensive interaction databases and the distinct metabolic profiles of both agents support the conclusion that no clinically meaningful interaction occurs.